Healthcare Services

Chronic Hepatitis B Market: Growth Potential and Future Outlook

April 20, 2026April 20, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Expansion In Market Value Is Forecasted For The Chronic Hepatitis B Market Between 2026 And 2030?

The market for chronic hepatitis B has shown consistent expansion over recent years. This market is projected to expand from $3.93 billion in 2025 to $4.1 billion by 2026, exhibiting a compound annual growth rate (CAGR) of 4.2%. Factors contributing to this historical growth include enhancements in hepatitis B screening initiatives, broader access to antiviral medications, increased public knowledge regarding liver disease complications, a rise in the application of nucleos(t)ide analogs, and the implementation of protocols for sustained disease monitoring.

The chronic hepatitis b market size is anticipated to experience consistent expansion over the upcoming years. Projections indicate it will reach $4.74 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 3.7%. This projected increase during the forecast period is primarily driven by heightened investments in advanced HBV therapies, a growing preference for finite-duration treatment protocols, the expansion of therapeutic vaccine research, an intensifying focus on eradicating viral reservoirs, and increased global efforts aimed at hepatitis elimination. Significant trends for the forecast period encompass the wider acceptance of long-term antiviral treatments, the surging development of functional cure methodologies, a stronger emphasis on early disease identification and surveillance, the broadening of immune-modulating treatment approaches, and improved programs for patient adherence.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/chronic-hepatitis-b-global-market-report

What Primary Drivers Are Shaping The Chronic Hepatitis B Market?

The anticipated expansion of the chronic hepatitis B virus market is linked to the widespread occurrence of chronic hepatitis B infection. This condition, a liver infection caused by the hepatitis B virus (HBV), can be prevented by vaccination. An uptick in hepatitis B infection rates stems from several contributing factors, especially in low- and middle-income countries, where inadequate vaccination coverage results in elevated transmission rates, leaving many people vulnerable. Such increases in infection rates are likely to boost the need for both diagnostic testing and therapeutic solutions. For example, a June 2024 report from the US government’s Centers for Disease Control and Prevention (CDC) indicated that achieving global hepatitis B vaccination coverage of 90% and treatment access of 80% could avert 26 million new infections and 9 million hepatitis B-related deaths between 2022 and 2050. Notably, 2022 saw 1.2 million new instances of hepatitis B virus (HBV) infection. Consequently, the widespread presence of hepatitis B infection is set to be a key driver for the chronic hepatitis B virus market.

Which Segments Define The Chronic Hepatitis B Market Segment Structure?

The chronic hepatitis b market covered in this report is segmented –

1) By Drug Class: Antivirals, Immune Modulators

2) By Gender: Male, Female

3) By Distribution Channel: Hospital Pharmacies, Drug Stores And Retail Pharmacies, Online Providers

Subsegments:

1) By Antivirals: Nucleos(T) Ide Analogs (Tenofovir, Entecavir), Interferons (Pegylated Interferon)

2) By Immune Modulators: Immune Checkpoint Inhibitors, Therapeutic Vaccines (HBV Vaccines Under Development)

What Trends Are Affecting The Growth Of The Chronic Hepatitis B Market?

Companies operating in the chronic hepatitis B market are prioritizing technological advancements, particularly novel antiviral therapies. These innovative medications are designed to combat viral infections, including drug-resistant strains, by inhibiting viral replication and utilizing advanced delivery methods. Their safety and effectiveness are currently being evaluated through ongoing clinical trials, with bepirovirsen being a notable example for chronic hepatitis B. For instance, in February 2024, GSK plc, a UK-based multinational pharmaceutical and biotechnology company, was granted the U.S. Food and Drug Administration (FDA) Fast Track designation for bepirovirsen. This investigational antisense oligonucleotide (ASO) is intended for the treatment of chronic hepatitis B (CHB). Bepirovirsen functions by targeting and degrading the RNA of the hepatitis B virus (HBV), which may enable the immune system to reassert control over the infection. The drug has exhibited encouraging outcomes in its Phase IIb trials, specifically the B-Clear and B-Sure studies, demonstrating its efficacy in lowering hepatitis B surface antigen (HBsAg) levels and achieving durable viral suppression.

Who Are The Established Players Within The Chronic Hepatitis B Market?

Major companies operating in the chronic hepatitis b market are Pfizer Inc., F Hoffmann-La Roche Ltd, Merck & Co Inc, Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Dynavax Technologies Corporation, Gilead Sciences Inc, Viatris Inc., Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Dr. Reddy’s Laboratories Ltd., Apotex Corp, Cipla Ltd, Hikma Pharmaceuticals, Lupin Pharmaceuticals Inc, Vir Biotechnology Inc, VBI Vaccines Inc, Shenzhen Hepalink Pharmaceutical Co. Ltd., Accord Healthcare Inc, Par Pharmaceutical Inc, Arrowhead Pharmaceuticals Inc, ViiV Healthcare, Arbutus Biopharma Corporation, Ascentage Pharma, ENYO Pharma, Zydus Pharmaceuticals Inc, Nucorion Pharmaceuticals

Get The Full Chronic Hepatitis B Market Report:

https://www.thebusinessresearchcompany.com/report/chronic-hepatitis-b-global-market-report

Which Region Is The Largest In The Chronic Hepatitis B Market?

North America was the largest region in the chronic hepatitis B market in 2025. The regions covered in the chronic hepatitis b market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Chronic Hepatitis B Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/chronic-hepatitis-b-global-market-report

Browse Through More Reports Similar to the Global Chronic Hepatitis B Market 2026, By The Business Research Company

Viral Hepatitis Market Report 2026

https://www.thebusinessresearchcompany.com/report/viral-hepatitis-global-market-report

Hepatitis B Virus Hbv Market Report 2026

https://www.thebusinessresearchcompany.com/report/hepatitis-b-virus-hbv-global-market-report

Preventive Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/preventive-vaccines-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795